Skip to main content

Table 2 Clinical characteristics of PCa patients (Cohort 2)a and the correlation with GM+CTCs and total CTCs

From: Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer

Clinical characteristics GM+CTCs Total CTCs
Subgroup Range n (Percentage) P/Nb P P/N P
Age (years) 48–86    0.770   >  0.999
  ≤ 70   27 (50.0%) 9/18   15/12  
  > 70   27 (50.0%) 8/19   15/12  
Gleason score 6–9    0.099   0.013*
  ≤ 7   28 (51.9%) 6/22   11/17  
  ≥ 8   26 (48.1%) 11/15   19/7  
Clinical Stage NA    0.003*   < 0.001*
 I + II   24 (44.4%) 2/22   7/17  
 III + IV   30 (55.6%) 15/15   23/7  
Metastasis NA    0.002*   0.007*
 No   25 (46.3%) 2/23   9/16  
 Yes   29 (53.7%) 15/14   21/8  
tPSA (ng/mL) 0.01–6000.0    0.003*   0.017*
  ≤ 20   24 (44.4%) 2/22   9/15  
  > 20   30 (55.6%) 15/15   21/9  
fPSA/tPSA 2.24–50.68    0.965   0.322
  ≤ 15%   32 (59.3%) 10/22   16/16  
  > 15%   22 (40.7%) 7/15   14/8  
ALP (U/L) 44–718    0.200   0.808
  ≤ 90   26 (48.1%) 6/20   14/12  
  > 90   28 (51.9%) 11/17   16/12  
Hb (g/L) 71–162    0.507   0.625
  ≤ 120   25 (46.3%) 9/16   13/12  
  > 120   29 (53.7%) 8/21   17/12  
  1. *P < 0.05
  2. aCohort 2 includes 54 patients pathologically diagnosed with prostate cancer
  3. bP: positive; N: negative. The positive criterion of CTCs test is ≥3/5 mL